Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 303

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 2
Chunk 303
---
 us to register the number of shares of Common Stock equal to 250% of the maximum number of Common Stock issuable
upon conversion of the Series D Preferred Stock (assuming for purposes hereof that (x) the Series D Preferred Stock is convertible at
the Alternate Conversion Price (as defined in the Series D Certificate of Designations) assuming an Alternate Conversion Date (as defined
in the Series D Certificate of Designations) of such date of determination, and (y) any such conversion shall not take into account any
limitations on the conversion of the Series D Preferred Stock set forth in the Series D Certificate of Designations).

July 2025 ELOC Transaction

On July 11, 2025, the Company
entered into an agreement to issue and sell 12,500,000 shares of Common Stock under the New Keystone Purchase Agreement. As the New Keystone
Purchase Agreement constitutes a continuation of the equity line program commenced under the February 2024 Purchase Agreement, the Commitment
Shares issued to the Investor pursuant to the February 2024 Purchase Agreement shall satisfy in full the Company’s obligation to
deliver any additional shares of Common Stock to the Investor as consideration for entering into the New Keystone Purchase Agreement.

Investigational New Drug
Application

In July 2025, CER-1236 received
an FDA Orphan Drug Designation for the treatment of acute myeloid leukemia. In September 2025, the FDA granted Fast Track Designation
to our lead investigational compound, CER-1236 for acute myeloid leukemia, which is in addition to the existing Orphan Drug Designation
for the same compound. The FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious
or life-threatening conditions with unmet medical need. The designation provides us with the opportunity for increased FDA interactions,
potential eligibility for priority review, and the ability to submit data on a rolling basis. Further, it also requires us to potentially
provide expanded access to the investigational drug on an as approved basis under pre-specified conditions.

Fifth PIPE Financing

On October 14, 2025, we entered
into the Fifth Securities Purchase Agreement, pursuant to which we agreed to issue and sell up to 9,750 shares of Series E Preferred Stock
for an aggregate purchase price of up to $7 million in one or more closings. On October 16, 2025, we and the requisite buyers party to
the Fifth Securities Purchase Agreement entered into Amendment No